Drug intelligence / Profile preview

RT301 + RT302

Development stage: Preclinical
Lead developer: Royaltechmed
Modality: Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

RT301 + RT302 is a combination mRNA-based therapeutic candidate being developed by Royaltechmed. Currently in the preclinical stage, the program utilizes an mRNA platform to address infectious diseases and renal cell carcinoma. The therapy is designed to deliver genetic instructions to cells, potentially inducing the expression of specific antigens or therapeutic proteins to stimulate an immune response against pathogens or malignant cells.

Other names: RT301~RT302

Beyond the preview

Go deeper on RT301 + RT302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RT301 + RT302.